肿瘤浸润性淋巴细胞在不同分子分型乳腺癌患者预后中的预测价值

doi:10.3969/j.issn.1009-976X.2024.01.012

摘要/Abstract

摘要： 肿瘤浸润性淋巴细胞（TILs）是肿瘤微环境的重要组成部分,在乳腺癌的抗肿瘤免疫应答中发挥着重要的作用。乳腺癌根据基因表达分析或免疫组织化学标记物雌激素受体（ER）、孕激素受体（PR）、人表皮生长因子受体2（HER2）的表达可以分为三阴性乳腺癌（TNBC）、HER2阳性乳腺癌、Luminal型乳腺癌,TILs对不同亚型的乳腺癌预后的预测价值不同。TILs对乳腺癌预后的不同不仅是因为TILs的浸润水平不同,也是因为TILs中同时存在有抗肿瘤和促肿瘤的亚群,不同患者中TILs的各种亚群也存在差异。

关键词: 肿瘤浸润性淋巴细胞, 三阴性乳腺癌, HER2阳性乳腺癌, Luminal型乳腺癌

Abstract: Tumor-infiltrating lymphocytes （TILs） are an important part of the tumor microenvironment and play an important role in the anti-tumor immune response of breast cancer. According to gene expression analysis or immunohistochemical markers of estrogen receptor （ER）, progesterone receptor （PR）, human epidermal growth factor receptor 2 （HER2） expression, breast cancer can be divided into triple negative breast cancer （TNBC）, HER2 positive breast cancer, Luminal breast cancer. The predictive value of TILs is different in different subtypes of breast cancer. The prognosis of TILs in breast cancer varies not only because of the different levels of TILs, but also because of the presence of both anti-tumor and pro-tumor subgroups in TILs, and the various subgroups of TILs differs in different patients.

Key words: tumor-infiltrating lymphocytes, triple negative breast cancer, HER2 positive breast cancer, luminal breast cancer

中图分类号:

R737.9

孟兰兰, 靳浩, 姚燕丹. 肿瘤浸润性淋巴细胞在不同分子分型乳腺癌患者预后中的预测价值[J]. 岭南现代临床外科, 2024, 24(01): 76-86.

MENG Lan-lan, JIN Hao, YAO Yan-dan. Predictive value of tumor infiltrating lymphocytes in breast cancer patients under different molecular subtypes[J]. Lingnan Modern Clinics In Surgery, 2024, 24(01): 76-86.

参考文献

[1] Siegel RL, Miller KD, Wagle N S, et al.Cancer statistics, 2023[J]. CA Cancer J Clin, 2023,73(1):17-48.
[2] Savas P, Salgado R, Denkert C, et al.Clinical relevance of host immunity in breast cancer: from TILs to the clinic[J]. Nat Rev Clin Oncol, 2016,13(4):228-241.
[3] Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breastcancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy[J]. Lancet Oncol, 2018,19(1):40-50.
[4] Stovgaard ES, Nielsen D, Hogdall E, et al.Triple negative breast cancer - prognostic role of immune-related factors: asystematic review[J]. Acta Oncol, 2018,57(1):74-82.
[5] Salgado R, Denkert C, Demaria S, et al.The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014[J]. Ann Oncol, 2015,26(2):259-271.
[6] Foulkes WD, Smith I E, Reis-Filho J S. Triple-negative breast cancer[J]. N Engl J Med, 2010,363(20):1938-1948.
[7] Loi S.Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy[J]. Oncoimmunology, 2013,2(7):e24720.
[8] Adams S, Gray RJ, Demaria S, et al.Prognostic value of tumor-infiltrating lymphocytes in triple-negativebreastcancers from two phase Ⅲ randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199[J]. J Clin Oncol, 2014, 32(27): 2959-2966.
[9] Loi S, Drubay D, Adams S, et al.Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual PatientAnalysis of Early-Stage Triple-Negative Breast Cancers[J]. J Clin Oncol, 2019,37(7):559-569.
[10] Park JH, Jonas SF, Bataillon G, et al.Prognostic value of tumor-infiltrating lymphocytes in patients with early-stagetriple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy[J]. Ann Oncol, 2019,30(12):1941-1949.
[11] Lotfinejad P, Asghari JM, Abdoli SM, et al.Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL)and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer(TNBC): A Systematic Review and Meta-Analysis Study[J]. Diagnostics (Basel), 2020,10(9).
[12] Kreutzfeldt J, Rozeboom B, Dey N, et al.The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies[J]. Am J Cancer Res, 2020,10(4):1045-1067.
[13] Cardoso F, Kyriakides S, Ohno S, et al.Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatmentand follow-updagger[J]. Ann Oncol, 2019,30(8):1194-1220.
[14] Whitford P, George WD, Campbell AM.Flow cytometric analysis of tumour infiltrating lymphocyte activation andtumourcell MHC class I and II expression in breast cancer patients[J]. Cancer Lett, 1992, 61(2): 157-164.
[15] Solinas C, Ceppi M, Lambertini M, et al.Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancertreated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or theircombination: A meta-analysis of randomized controlled trials[J]. Cancer Treat Rev, 2017,57:8-15.
[16] Fernandez-Martinez A, Pascual T, Singh B, et al.Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vsTumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials[J]. JAMA Oncol, 2023,9(4):490-499.
[17] Perez EA, Ballman KV, Tenner KS, et al.Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-FreeSurvival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-PositiveBreast Cancer[J]. JAMA Oncol, 2016,2(1):56-64.
[18] Wu R, Oshi M, Asaoka M, et al.Intratumoral Tumor Infiltrating Lymphocytes (TILs) are Associated With CellProliferation and Better Survival But Not Always With Chemotherapy Response inBreast Cancer[J]. Ann Surg, 2023,278(4):587-597.
[19] Luen SJ, Salgado R, Fox S, et al.Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treatedwith pertuzumab or placebo in addition to trastuzumab and docetaxel: aretrospective analysis of the CLEOPATRA study[J]. Lancet Oncol, 2017,18(1):52-62.
[20] Luen S, Virassamy B, Savas P, et al.The genomic landscape of breast cancer and its interaction with host immunity[J]. Breast, 2016,29:241-250.
[21] Ali HR, Provenzano E, Dawson SJ, et al.Association between CD8+ T-cell infiltration and breast cancer survival in 12,439patients[J]. Ann Oncol, 2014,25(8):1536-1543.
[22] Zhang J, Abubakar M, Yuan P, et al.Prognostic significance of tumor-infiltrating lymphocytes in premenopausal, luminal breast cancer treated with adjuvant endocrine therapy[J].Am J Transl Res, 2021,13(11):12750-12762.
[23] Gao ZH, Li CX, Liu M, et al.Predictive and prognostic role of tumour-infiltrating lymphocytes in breastcancer patients with different molecular subtypes: a meta-analysis[J]. BMC Cancer, 2020,20(1):1150.
[24] Watanabe T, Hida AI, Inoue N, et al.Abundant tumor infiltrating lymphocytes after primary systemic chemotherapypredicts poor prognosis in estrogen receptor-positive/HER2-negative breastcancers[J]. Breast Cancer Res Treat, 2018,168(1):135-145.
[25] Ahn SG, Cha YJ, Bae S J, et al.Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrencescore in ER-positive/HER2-negative breast cancer[J]. BMC Cancer, 2018,18(1):320.
[26] Pousette J, Johansson A, Jönsson C, et al.Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2-Negative Postmenopausal Breast Cancer Patients[J]. Cancers (Basel), 2022, 14(19): 4844.
[27] Nederlof I, Hajizadeh S, Sobhani F, et al.Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positiveHER2-negative breast cancer[J]. NPJ Breast Cancer, 2022,8(1):56.
[28] Kroemer G, Senovilla L, Galluzzi L, et al.Natural and therapy-induced immunosurveillance in breast cancer[J]. Nat Med, 2015,21(10):1128-1138.
[29] Bui JD, Schreiber RD.Cancer immunosurveillance, immunoediting and inflammation: independent orinterdependent processes?[J]. Curr Opin Immunol, 2007,19(2):203-208.
[30] Paijens ST, Vledder A, de Bruyn M, et al. Tumor-infiltrating lymphocytes in the immunotherapy era[J]. Cell Mol Immunol, 2021,18(4):842-859.
[31] 吉芃, 龚悦, 狄根红. 肿瘤浸润淋巴细胞在三阴性乳腺癌和HER2阳性乳腺癌中作用的最新研究进展[J].中国癌症杂志, 2018,28(12):928-934.
[32] Takeya M, Komohara Y.Role of tumor-associated macrophages in human malignancies: friend or foe?[J]. Pathol Int, 2016,66(9):491-505.
[33] Tan AH, Goh SY, Wong SC, et al.T helper cell-specific regulation of inducible costimulator expression viadistinct mechanisms mediated by T-bet and GATA-3[J]. J Biol Chem, 2008,283(1):128-136.
[34] Stanton SE, Disis ML.Clinical significance of tumor-infiltrating lymphocytes in breast cancer[J]. J Immunother Cancer, 2016,4:59.
[35] Nelson MA, Ngamcherdtrakul W, Luoh SW, et al.Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes inbreast cancer[J]. Cancer Metastasis Rev, 2021,40(2):519-536.
[36] Basu A, Ramamoorthi G, Albert G, et al.Differentiation and Regulation of T(H) Cells: A Balancing Act for CancerImmunotherapy[J]. Front Immunol, 2021,12:669474.
[37] Yang B, Chou J, Tao Y, et al.An assessment of prognostic immunity markers in breast cancer[J]. NPJ Breast Cancer, 2018,4:35.
[38] Zhou Y, Tian Q, Gao H, et al.Immunity and Extracellular Matrix Characteristics of Breast Cancer Subtypes Basedon Identification by T Helper Cells Profiling[J]. Front Immunol, 2022,13:859581.
[39] Bates GJ, Fox SB, Han C, et al.Quantification of regulatory T cells enables the identification of high-riskbreast cancer patients and those at risk of late relapse[J]. J Clin Oncol, 2006,24(34):5373-5380.
[40] Merlo A, Casalini P, Carcangiu ML, et al.FOXP3 expression and overall survival in breast cancer[J]. J Clin Oncol, 2009,27(11):1746-1752.
[41] Liu S, Foulkes WD, Leung S, et al.Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancerdepends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration[J]. Breast Cancer Res, 2014,16(5):432.
[42] Nunez NG, Tosello BJ, Ramos RN, et al.Tumor invasion in draining lymph nodes is associated with Treg accumulation inbreast cancer patients[J]. Nat Commun, 2020,11(1):3272.
[43] Jaaskelainen MM, Tiainen S, Siiskonen H, et al.The prognostic and predictive role of tumor-infiltrating lymphocytes (FoxP3 + andCD8 +) and tumor-associated macrophages in early HER2 + breast cancer[J]. Breast Cancer Res Treat, 2023,201(2):183-192.
[44] Mahmoud SM, Paish EC, Powe DG, et al.Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer[J]. J Clin Oncol, 2011,29(15):1949-1955.
[45] Baker K, Lachapelle J, Zlobec I, et al.Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon bothoestrogen receptor status and histological grade[J]. Histopathology, 2011,58(7):1107-1116.
[46] Althobiti M, Aleskandarany MA, Joseph C, et al.Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and itsprognostic significance[J]. Histopathology, 2018,73(6):887-896.
[47] Papaioannou E, Sakellakis M, Melachrinou M, et al.A Standardized Evaluation Method for FOXP3+ Tregs and CD8+ T-cells in Breast Carcinoma: Association With Breast Carcinoma Subtypes, Stage and Prognosis[J]. Anticancer Res, 2019,39(3):1217-1232.
[48] Oshi M, Asaoka M, Tokumaru Y, et al.CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer[J]. Int J Mol Sci, 2020, 21(18): 6968.
[49] Savas P, Virassamy B, Ye C, et al.Single-cell profiling of breast cancer T cells reveals a tissue-resident memorysubset associated with improved prognosis[J]. Nat Med, 2018,24(7):986-993.
[50] Sobral-Leite M, Salomon I, Opdam M, et al.Cancer-immune interactions in ER-positive breast cancers: PI3K pathwayalterations and tumor-infiltrating lymphocytes[J]. Breast Cancer Res, 2019,21(1):90.
[51] Lanier LL.Up on the tightrope: natural killer cell activation and inhibition[J]. Nat Immunol, 2008,9(5):495-502.
[52] Mamessier E, Sylvain A, Thibult ML, et al.Human breast cancer cells enhance self tolerance by promoting evasion from NKcell antitumor immunity[J]. J Clin Invest, 2011,121(9):3609-3622.
[53] Rezaeifard S, Talei A, Shariat M, et al.Tumor infiltrating NK cell (TINK) subsets and functional molecules in patientswith breast cancer[J]. Mol Immunol, 2021,136:161-167.
[54] Tian X, Wei F, Wang L, et al.Herceptin Enhances the Antitumor Effect of Natural Killer Cells on Breast CancerCells Expressing Human Epidermal Growth Factor Receptor-2[J]. Front Immunol, 2017,8:1426.
[55] Muntasell A, Rojo F, Servitja S, et al.NK Cell Infiltrates and HLA Class I Expression in Primary HER2(+) Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival[J]. Clin Cancer Res, 2019,25(5):1535-1545.
[56] Bouzidi L, Triki H, Charfi S, et al.Prognostic Value of Natural Killer Cells Besides Tumor-Infiltrating Lymphocytesin Breast Cancer Tissues[J]. Clin Breast Cancer, 2021,21(6):e738-e747.
[57] Cassetta L, Pollard JW.Targeting macrophages: therapeutic approaches in cancer[J]. Nat Rev Drug Discov, 2018,17(12):887-904.
[58] Tkach M, Thalmensi J, Timperi E, et al.Extracellular vesicles from triple negative breast cancer promotepro-inflammatory macrophages associated with better clinical outcome[J]. Proc Natl Acad Sci U S A, 2022,119(17):e2107394119.
[59] Woo SM, Choi YK, Cho SG, et al.A New Herbal Formula, KSG-002, Suppresses Breast Cancer Growth and Metastasis by Targeting NF-kappa B-Dependent TNF alpha Production in Macrophages[J]. Evid Based Complement Alternat Med, 2013,2013:728258.
[60] Williams CB, Yeh ES, Soloff AC.Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy[J]. NPJ Breast Cancer, 2016,2:15025.
[61] Allison E, Edirimanne S, Matthews J, et al.Breast Cancer Survival Outcomes and Tumor-Associated Macrophage Markers: ASystematic Review and Meta-Analysis[J]. Oncol Ther, 2023,11(1):27-48.
[62] Weng YS, Tseng HY, Chen YA, et al.MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemnessand M2 macrophage polarization in triple-negative breast cancer[J]. Mol Cancer, 2019,18(1):42.
[63] Honkanen TJ, Tikkanen A, Karihtala P, et al.Prognostic and predictive role of tumour-associated macrophages in HER2 positivebreast cancer[J]. Sci Rep, 2019,9(1):10961.
[64] Chen Y, Zhang S, Wang Q, et al.Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis viaM2 macrophage-secreted CHI3L1 protein[J]. J Hematol Oncol, 2017,10(1):36.
[65] Yang J, Li X, Liu X, et al.The role of tumor-associated macrophages in breast carcinoma invasion andmetastasis[J]. Int J Clin Exp Pathol, 2015,8(6):6656-6664.
[66] Campbell MJ, Tonlaar NY, Garwood ER, et al.Proliferating macrophages associated with high grade, hormone receptor negativebreast cancer and poor clinical outcome[J]. Breast Cancer Res Treat, 2011,128(3):703-711.
[67] Jamiyan T, Kuroda H, Yamaguchi R, et al.CD68- and CD163-positive tumor-associated macrophages in triple negative cancerof the breast[J]. Virchows Arch, 2020,477(6):767-775.
[68] Adams TA, Vail PJ, Ruiz A, et al.Composite analysis of immunological and metabolic markers defines novel subtypesof triple negative breast cancer[J]. Mod Pathol, 2018,31(2):288-298.
[69] Zhao X, Qu J, Sun Y, et al.Prognostic significance of tumor-associated macrophages in breast cancer: ameta-analysis of the literature[J]. Oncotarget, 2017,8(18):30576-30586.
[70] Allison E, Edirimanne S, Matthews J, et al.Breast Cancer Survival Outcomes and Tumor-Associated Macrophage Markers: ASystematic Review and Meta-Analysis[J]. Oncol Ther, 2023,11(1):27-48.
[71] Wennhold K, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M. B Cell-Based Cancer Immunotherapy[J]. Transfus Med Hemother, 2019,46(1):36-46.
[72] Lund FE, Randall TD.Effector and regulatory B cells: modulators of CD4+ T cell immunity[J]. Nat Rev Immunol, 2010,10(4):236-247.
[73] Wouters M, Nelson BH.Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer[J]. Clin Cancer Res, 2018,24(24):6125-6135.
[74] Zhang Z, Zhu Y, Wang Z, et al.Yin-yang effect of tumor infiltrating B cells in breast cancer: From mechanism toimmunotherapy[J]. Cancer Lett, 2017,393:1-7.
[75] Shen M, Wang J, Ren X.New Insights into Tumor-Infiltrating B Lymphocytes in Breast Cancer: ClinicalImpacts and Regulatory Mechanisms[J]. Front Immunol, 2018,9:470.
[76] Xu Y, Lan S, Zheng Q.Prognostic significance of infiltrating immune cell subtypes in invasive ductalcarcinoma of the breast[J]. Tumori, 2018,104(3):196-201.
[77] Brown JR, Wimberly H, Lannin DR, et al.Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response toneoadjuvant chemotherapy in breast cancer[J]. Clin Cancer Res, 2014,20(23):5995-6005.
[78] Song IH, Heo SH, Bang WS, et al.Predictive Value of Tertiary Lymphoid Structures Assessed by High EndothelialVenule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer[J]. Cancer Res Treat, 2017,49(2):399-407.
[79] Arias-Pulido H, Cimino-Mathews A, Chaher N, et al.The combined presence of CD20 + B cells and PD-L1 + tumor-infiltratinglymphocytes in inflammatory breast cancer is prognostic of improved patientoutcome[J]. Breast Cancer Res Treat, 2018,171(2):273-282.
[80] Yu H, Yang J, Jiao S, et al.[Prognostic value of B lymphocyte infiltration in breast cancer][J]. Nan Fang Yi Ke Da Xue Xue Bao, 2013,33(5):750-755.
[81] Mohammed ZM, Going JJ, Edwards J, et al.The relationship between lymphocyte subsets and clinico-pathological determinantsof survival in patients with primary operable invasive ductal breast cancer[J]. Br J Cancer, 2013,109(6):1676-1684.
[82] Miligy I, Mohan P, Gaber A, et al.Prognostic significance of tumour infiltrating B lymphocytes in breast ductalcarcinoma in situ[J]. Histopathology, 2017,71(2):258-268.